2023 annual financial data
4D Molecular Therapeutics 2023 Operating margin
Direct answer
Operating margin was -544.65%.
Operating income was -112,867,000 USD and net income was -100,837,000 USD.
Operating cash flow was -75,792,000 USD.
Get free 4D Molecular Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 20,723,000 USD
- Operating income
- -112,867,000 USD
- Net income
- -100,837,000 USD
- Operating cash flow
- -75,792,000 USD